These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 16302717)

  • 21. Combined therapy with GnRH analog plus growth hormone in central precocious puberty.
    Pucarelli I; Segni M; Ortore M; Moretti A; Iannaccone R; Pasquino AM
    J Pediatr Endocrinol Metab; 2000 Jul; 13 Suppl 1():811-20. PubMed ID: 10969926
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Final height in central precocious puberty after long term treatment with a slow release GnRH agonist.
    Oostdijk W; Rikken B; Schreuder S; Otten B; Odink R; Rouwé C; Jansen M; Gerver WJ; Waelkens J; Drop S
    Arch Dis Child; 1996 Oct; 75(4):292-7. PubMed ID: 8984913
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Longitudinal study of behavioral and affective patterns in girls with central precocious puberty during long-acting triptorelin therapy.
    Xhrouet-Heinrichs D; Lagrou K; Heinrichs C; Craen M; Dooms L; Malvaux P; Kanen F; Bourguignon JP
    Acta Paediatr; 1997 Aug; 86(8):808-15. PubMed ID: 9307158
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of central precocious puberty with triptorelin 11.25 mg depot formulation.
    Martínez-Aguayo A; Hernández MI; Beas F; Iñiguez G; Avila A; Sovino H; Bravo E; Cassorla F
    J Pediatr Endocrinol Metab; 2006 Aug; 19(8):963-70. PubMed ID: 16995580
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Precocious puberty in children with myelomeningocele: treatment with gonadotropin-releasing hormone analogues.
    Trollmann R; Strehl E; Dörr HG
    Dev Med Child Neurol; 1998 Jan; 40(1):38-43. PubMed ID: 9459215
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of triptorelin 6-month formulation in patients with central precocious puberty.
    Klein K; Yang J; Aisenberg J; Wright N; Kaplowitz P; Lahlou N; Linares J; Lundström E; Purcea D; Cassorla F
    J Pediatr Endocrinol Metab; 2016 Nov; 29(11):1241-1248. PubMed ID: 26887034
    [TBL] [Abstract][Full Text] [Related]  

  • 27. End results in central precocious puberty with GnRH analog treatment: the data of the Italian Study Group for Physiopathology of Puberty.
    Antoniazzi F; Arrigo T; Cisternino M; Galluzzi F; Bertelloni S; Pasquino AM; Borrelli P; Osio D; Mengarda F; De Luca F; Tatò L
    J Pediatr Endocrinol Metab; 2000 Jul; 13 Suppl 1():773-80. PubMed ID: 10969920
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adult height in girls with idiopathic true precocious puberty.
    Brauner R; Adan L; Malandry F; Zantleifer D
    J Clin Endocrinol Metab; 1994 Aug; 79(2):415-20. PubMed ID: 8045957
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sexual precocity in boys: accelerated versus slowly progressive puberty gonadotropin-suppressive therapy and final height.
    Lazar L; Pertzelan A; Weintrob N; Phillip M; Kauli R
    J Clin Endocrinol Metab; 2001 Sep; 86(9):4127-32. PubMed ID: 11549638
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment of children with central precocious puberty by a slow-release gonadotropin-releasing hormone agonist.
    Oostdijk W; Hümmelink R; Odink RJ; Partsch CJ; Drop SL; Lorenzen F; Sippell WG; van der Velde EA; Schultheiss H
    Eur J Pediatr; 1990 Feb; 149(5):308-13. PubMed ID: 2138079
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Long-term experiences with a long-acting gonadotropin releasing hormone analog in therapy of central precocious puberty: effect on body growth].
    Hofmann-Ehrhart B; Schulz U; Kluge M; Wandl-Vergesslich K; Waldhauser F
    Wien Klin Wochenschr; 1995; 107(14):413-7. PubMed ID: 7668000
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antagonistic and agonistic GnRH analogue treatment of precocious puberty: tracking gonadotropin concentrations in urine.
    Roth CL; Brendel L; Rückert C; Hartmann K
    Horm Res; 2005; 63(5):257-62. PubMed ID: 15995342
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Triptorelin depot for the treatment of children 2 years and older with central precocious puberty.
    Bertelloni S; Mucaria C; Baroncelli GI; Peroni D
    Expert Rev Clin Pharmacol; 2018 Jul; 11(7):659-667. PubMed ID: 29957076
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Treatment of precocious puberty with an LH-RH agonist (D-TRP6-LH-RH)].
    Couprie C; Roger M; Chaussain JL
    J Steroid Biochem; 1989 Oct; 33(4B):805-8. PubMed ID: 2532270
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Use of a potent, long acting agonist of gonadotropin-releasing hormone in the treatment of precocious puberty.
    Boepple PA; Mansfield MJ; Wierman ME; Rudlin CR; Bode HH; Crigler JF; Crawford JD; Crowley WF
    Endocr Rev; 1986 Feb; 7(1):24-33. PubMed ID: 2937629
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-acting GnRH analogue triptorelin therapy in central isosexual precocious puberty.
    Bajpai A; Sharma J; Kabra M; Gupta AK; Menon PS
    Indian Pediatr; 2002 Jul; 39(7):633-9. PubMed ID: 12147888
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reproductive axis after discontinuation of gonadotropin-releasing hormone analog treatment of girls with precocious puberty: long term follow-up comparing girls with hypothalamic hamartoma to those with idiopathic precocious puberty.
    Feuillan PP; Jones JV; Barnes K; Oerter-Klein K; Cutler GB
    J Clin Endocrinol Metab; 1999 Jan; 84(1):44-9. PubMed ID: 9920060
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Central precocious puberty: treatment with triptorelin 11.25 mg.
    Chiocca E; Dati E; Baroncelli GI; Cassio A; Wasniewska M; Galluzzi F; Einaudi S; Cappa M; Russo G; Bertelloni S
    ScientificWorldJournal; 2012; 2012():583751. PubMed ID: 22645436
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fertility of Women Treated during Childhood with Triptorelin (Depot Formulation) for Central Precocious Puberty: The PREFER Study.
    Martinerie L; de Mouzon J; Blumberg J; di Nicola L; Maisonobe P; Carel JC;
    Horm Res Paediatr; 2020; 93(9-10):529-538. PubMed ID: 33774631
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term outcome after depot gonadotropin-releasing hormone agonist treatment of central precocious puberty: final height, body proportions, body composition, bone mineral density, and reproductive function.
    Heger S; Partsch CJ; Sippell WG
    J Clin Endocrinol Metab; 1999 Dec; 84(12):4583-90. PubMed ID: 10599723
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.